New mpox variant confirmed in Toronto
Toronto has reported two travel-related cases of the new mpox variant, known as Clade Ib. This development raises significant public health concerns, particularly as Clade Ib is associated with outbreaks in Central and Eastern Africa.
The total number of confirmed mpox cases in Toronto reached 155 by the end of 2025, indicating a growing need for vigilance and preventive measures. Symptoms of mpox include fever, chills, headache, muscle aches, fatigue, and rash, which can lead to serious health issues if not addressed promptly.
Toronto Public Health has stated that the mpox vaccine is available for eligible residents through various clinics and community partners. Importantly, the vaccine is free and accessible with or without a health card, ensuring that individuals can receive protection against this variant.
Individuals who have already received two doses of the mpox vaccine do not require additional vaccinations, which simplifies the public health response. Treatment guidance for mpox remains unchanged, allowing healthcare providers to continue their current protocols.
Health officials have noted that while the current risk appears contained, the situation is fluid, and public sentiment can shift rapidly in response to new information. “Current risk appears contained, but headlines can shift sentiment fast,” a health official remarked.
Clade Ib is considered more severe than the previously identified Clade 2b, which was reported in a few cases in Toronto back in 2022. Both variants can cause painful skin lesions, fever, and other flu-like symptoms, underscoring the importance of awareness and preventive measures.
The virus can be transmitted through close, intimate, or sexual contact with an infected person, making it crucial for individuals to be informed about the risks and symptoms associated with mpox.
As the situation develops, health authorities are closely monitoring the cases and will provide updates as necessary. Details remain unconfirmed regarding the full extent of the variant’s spread and its implications for public health.
